Connect with us

Fertility

Eight in ten Brits consider stopping IVF treatment due to costs, research reveals

The study found that two thirds of people in the UK expect their employer to cover IVF

Published

on

Brits are struggling to cope with the costs of IVF and expect more support from their employers, a new study has shown.

The virtual fertility clinic Apricity conducted a survey of 500 people in the UK who are either undergoing fertility treatment (40 per cent) or preparing for fertility treatments (60 per cent).

It found that 84 per cent of the patients surveyed funded their treatment themselves, with the NHS covering only about 20 per cent of treatments.

One cycle of IVF with medication costs upwards of £7,000 and at least three cycles are recommended for success.

This put huge financial pressure on patients who struggled to pay for their treatment, despite the average income of respondents was £31,400.

The waiting time is between one and two years in England, and whether you are able to access NHS fertility treatment depends on your GP’s postcode, with different regions offering different levels of access to NHS IVF and some offering none at all.

Women can be eligible for three rounds of NHS-funded IVF treatment if they have been trying unsuccessfully to start a family for two or more years, or if they have had 12 or more unsuccessful rounds of artificial insemination.

Approximately 81 per cent of participants surveyed by Apricity considered giving up treatment while 39 per cent only went through two of the three cycles needed for full treatment due to financial pressure.

The study also showed that 57 per cent of patients did not understand the true financial costs at stake before starting treatment.

Almost two thirds said they would expect their employer to cover these costs, either in full or part, and 82 per cent said they would only consider working for an employer that offered fertility benefits if they were looking to do IVF again. 

Fertility treatment is a significant time commitment, which can take up months of a patient’s life.

While 84 per cent of respondents had to take time off during treatment, more than a third (38 per cent) took this time off under annual leave and a further 16 per cent took no time off at all.

Additionally, 62 per cent of UK responders found fertility treatment just as, if not more stressful than losing their job, with half of them finding it just as if not more stressful than the bereavement of a close loved one.

“With the private sector taking up the vast majority of the UK fertility market and the NHS under massive strain, more people are looking to their employers to step up and support them on their fertility journey both financially and with flexible working,” said Caroline Noublanche, founder and CEO of Apricity.

“This is currently much more common in the US, where 81 per cent of the best workplaces are providing reimbursement for fertility treatments compared to just 17 per cent already in place in the UK.

“At Apricity we’re working to make the fertility journey as smooth and stress-free as possible, and have already partnered with some of the largest UK employers, insurers and employee benefit platforms including Axa PPP, Reward Gateway and Mercer Marsh, and we expect more to join us offering fertility benefits.

“We try to remove a lot of the disruption for patients and employers alike by significantly reducing the number of visits to the clinic.”

She added: “If more employers supported the process and more clinics used new technology solutions, we’d be able to collectively better manage the process and reduce the stigma.”

The study also found that fertility treatment is likely to have negative consequences for both romantic and personal relationships, with 80 per cent of couples saying it caused friction in their relationship.

Half  of respondents chose no to tell friends/family about their IVF treatments, with shame and embarrassment cited as the main reason.

Insight

UK reviews surrogacy firm over rejected insurance claims

Published

on

The UK government is reviewing a surrogacy firm after complaints that medical insurance claims involving surrogates in Mexico were rejected.

The Department of Health and Social Care (DHSC) is considering whether UK-based provider My Surrogacy Journey should remain listed on gov.uk as one of four domestic surrogacy agencies available to intended parents.

The review follows allegations concerning its Mexican sister company, where surrogates are based.

Health minister Diana Johnson said: “The department is looking into the allegations about My Surrogacy Journey.

“As part of that assessment, the department will consider whether it is appropriate for that company to remain on the gov.uk list of agencies.”

Emails sent by My Surrogacy Journey chief executive Michael Johnson-Ellis and seen by the Guardian suggest multiple surrogate women in Mexico had their insurance claims rejected.

The emails also suggest 300 couples using the company were moved to a new insurance provider because of the increased risk of claims being rejected.

Commercial surrogacy is banned in the UK, where only altruistic arrangements are permitted.

My Surrogacy Journey operates a not-for-profit UK branch alongside for-profit sister companies in Mexico and the US. All three companies have the same owners and chief executives.

The reported insurance issues relate to surrogacy arrangements in Mexico.

One couple told the Guardian they paid tens of thousands of pounds to cover medical costs after their surrogate had a hysterectomy during childbirth and an insurance claim was refused.

The Guardian said it understood that at least five sets of parents said they had to cover medical costs after insurance claims were rejected.

In an email to the couple whose surrogate underwent a hysterectomy, Johnson-Ellis wrote: “We have already told you that the insurance companies have been declining some of the claims and we are actively working with the broker to get this issue resolved but you should also consider that they may not be paid out and there is nothing we are able to do to change this …

“We appreciate this is not an insignificant sum but this genuinely is out of our control.”

Johnson-Ellis also said the company had switched insurance providers, writing: “We’re also managing this for 300 other journeys, which is a complex position to be in.”

Lawyers acting for My Surrogacy Journey said the company did not comment on individual cases, but that existing insurance policies were in place and claims continued to be accepted and processed.

They said the company understood that a small number of claims had been rejected and was supporting people seeking to resolve those claims with an insurer.

Under the surrogacy arrangements, intended parents are understood to be contractually required to cover medical costs not paid by an insurer.

The couple said they had been recommended the company’s Mexico option. Its website advertises that intended parents using the route can have a baby in “under 18 months”.

They said they were told the UK route could take up to five years and that the US option was much more expensive.

Lawyers for My Surrogacy Journey said prospective parents are given information about typical timelines, costs, legal frameworks and practical considerations, and that the 18-month timeframe is indicative only.

The couple said their surrogate developed placenta accreta, a serious condition in which the placenta attaches to the wall of the uterus.

Emails from Johnson-Ellis acknowledged that the insurance provider investigated the birth after the surrogate experienced health complications.

The parents are considering legal action, while the Guardian said it understood at least four other couples were reviewing their options.

Phil Brickell, MP for Bolton West, raised concerns in parliament about a separate couple who had used My Surrogacy Journey.

He said: “Two of my constituents recently travelled to Mexico, where their children were born by surrogacy.

“Those births were facilitated by a company called My Surrogacy Journey, which is listed on gov.uk.

“While in Mexico, they had repeated traumatic experiences with the company relating to issues including insurance for their children, accusations of bullying towards staff and repeated efforts to silence any constructive criticism.

“I understand that other members of this house have received similar complaints.”

Brickell called for My Surrogacy Journey to be removed from gov.uk pending a review by the Human Fertilisation and Embryology Authority.

Lawyers acting for My Surrogacy Journey said the company was communicating with DHSC and was confident any issues could be resolved.

Continue Reading

Fertility

Spain football federation partnership to offer players egg-freezing and fertility treatment

Published

on

Spain’s football federation will offer national team players egg-freezing and fertility treatment through a clinic partnership running until 2029.

The agreement with the Tambre clinic in Madrid will give Spain’s World Cup winners more options to pursue motherhood when they feel the time is right.

The Royal Spanish Football Federation (RFEF) said the agreement covers all national team players, including the futsal team, as well as Primera Division referees and assistants and all other federation employees.

It is the latest policy introduced by the RFEF as it seeks to lead the way in work-life balance and maternity protection.

The federation has also introduced measures allowing players to travel with their children during major tournaments. The scheme was extended to the men’s team during their successful World Cup campaign in North America this past summer.

RFEF president Rafael Louzán said: “If Spain and its national teams are the best in the world on the pitch, they must also be the best in matters such as work-life balance.

“This is a new, comprehensive and pioneering benefit that extends to all federation employees. Today is a great day for the entire Spanish football family.”

The agreement followed a direct request from players after discussions with national team captains, including London City Lionesses midfielder Alexia Putellas.

Putellas told Spanish outlet El País: “As a group of captains, we had a concern — because experiencing a World Cup is vital for a player — regarding the difficulty of reconciling that with the desire to become a mother.”

“It’s a desire I didn’t originally have but developed some time ago.

“Thanks to the incredible work done by the federation, an agreement has been reached with a clinic allowing us to freeze our eggs while we are still active players, for as long as we wish.

“For me, this is a huge step forward; the federation understands that you are serving your country in a way that runs counter to your biological clock — that you can’t simply pause your career to become a mother because you need your body to do your job.”

The announcement follows Chelsea becoming the first Women’s Super League club to offer similar fertility treatment options to its players.

The move has also drawn criticism.

Spanish triple jumper Ana Peleteiro-Compaoré Brión said on Instagram: “The problem obviously isn’t freezing eggs.

“The problem is: why does the institution these women work for have an interest in financing them to delay their motherhood?

“And here there’s a problem that for me changes absolutely everything.

“Is this measure intended to make it easier for women to be mothers or is it intended to make it easier for them not to be while they’re playing?”

Spain are the current world champions in both the women’s and men’s games.

The women will attempt to defend their title at the 2027 World Cup in Brazil next summer.

Continue Reading

Fertility

Paracetamol use may impact future fertility, studies suggest

Published

on

Paracetamol use in pregnancy was not linked to autism or ADHD, while separate research found reproductive differences in girls exposed before birth.

One study analysed health records from more than 120,000 children and found no increased risk of autism following prenatal paracetamol exposure.

A separate analysis of nearly 100,000 children also found no increased risk of ADHD among those born to mothers who used the painkiller during pregnancy.

Researchers from the Hong Kong Hospital Authority examined electronic health records covering pregnancies between January 2001 and December 2023.

The autism analysis included 124,333 children, who were nine years old on average and split almost evenly between males and females. There were 3,445 autism diagnoses, representing 2.8 per cent of the group.

The ADHD analysis involved 97,285 children, who were seven years old on average and also split evenly between males and females. There were 5,168 ADHD diagnoses, representing 5.3 per cent.

Women prescribed paracetamol during pregnancy were more likely to be older and have pre-existing conditions including psychiatric disorders, as well as reasons for taking the drug such as infection, fever or chronic pain.

No association was found between prenatal paracetamol exposure and either autism or ADHD.

The findings did not differ according to the trimester in which paracetamol was taken or whether use was intermittent or daily. Advanced maternal age, defined as pregnancy in women over 35, did not alter the findings.

The researchers wrote: “Paracetamol remains a safe and essential analgesic [pain reliever] and antipyretic [fever reducer] during pregnancy, whereas alternatives, such as NSAIDs and opioids carry well-documented risks.

“Unwarranted reluctance to use paracetamol could lead to undertreatment of pain and fever, or the use of more harmful alternatives, both posing risks to the pregnancy and developing fetus.”

The authors said women should assess paracetamol use with guidance from their doctor.

A separate study involving 685 pregnant women without pre-existing conditions and 302 infant daughters found associations between prenatal paracetamol exposure and differences in reproductive organs and hormone levels.

Researchers from Copenhagen University Hospital enrolled the women during their first trimester and assessed them during the first trimester, third trimester and again when their babies were three months old.

At around three months, infants experience a temporary rise in reproductive hormones sometimes called mini-puberty.

Pregnant participants completed questionnaires every two weeks about their use of pain medicines including paracetamol. Infant girls underwent ultrasound scans of their reproductive organs and blood tests to measure hormone levels.

Researchers also examined a separate group of 1,210 girls followed from infancy to adolescence whose mothers reported paracetamol use during the third trimester.

Three-month-old girls exposed to paracetamol before birth had an average 40 per cent smaller ovarian volume, 13 per cent smaller uterine volume and 23 per cent fewer ovarian follicles.

Girls exposed during the first trimester also had lower levels of Anti-Müllerian hormone, a marker of ovarian function.

Among the older girls, those exposed before birth were more likely to have smaller uteruses at puberty and smaller ovaries during their teenage years.

Dr Margit Bistrup Fischer, lead study author and postdoctoral researcher in the Department of Growth and Reproduction at Rigshospitalet hospital in Denmark, said: “Animal studies have demonstrated that impaired formation of ovarian follicles can lead to reduced fertility and earlier reproductive aging.

“Whether the differences observed in our study have implications for fertility and age at menopause in humans remains unknown and will require long-term follow-up of the girls in our cohort.”

She cautioned that women who had used paracetamol during pregnancy “should not be alarmed by our findings”, as the study found associations rather than direct causation and outcomes for individual women and children are unclear.

“Importantly, our study does not evaluate whether [acetaminophen] causes reproductive problems, nor does it provide evidence that prenatal exposure affects future fertility or age at menopause,” she said.

“Although we observed similar associations in an independent cohort, long-term follow-up is needed to determine whether these early-life differences have any clinical significance later in life.”

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.